The expression of SOX9, a transcription factor involved in proliferation, self-renewal, and tumorigenicity of cancer stem cells [36], was slightly, albeit not significantly, reduced by the treatment with sorafenib (Figure 4D and Figure S4). This evidence concerns the gene SOX9 and cancer.